Ascend, Mayne settle with US states for $1m in generic-drug antitrust case
( October 8, 2026, 20:01 GMT | Official Statement) -- MLex Summary: Ascend Laboratories and Mayne Pharma agreed to pay $1 million to settle US antitrust claims filed by 48 state attorneys general over generic drug pricing, New York Attorney General Letitia James announced. “Millions of New Yorkers depend on affordable generic drugs to treat heart conditions, diabetes, and a range of other health issues,” James said. “These companies illegally colluded to raise generic drug prices and pad their profits at consumers’ expense.” The agreement is subject to approval by a federal judge.Statement follows in full. Also see attached file. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.